Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly. Novo Nordisk also lost a bidding war for a promising start-up. Novo Nordisk ...

AI-generated summary reviewed by our newsroom. Read our AI Policy. North Carolina clinics first noted weight loss from GLP‑1 diabetes drugs in 2016. GLP‑1 medicines suppress appetite and triggered a ...